10-Q Filing

Astrana Health, Inc. CIK: 1083446 Q2 2017

Filing Information

Form Type	10-Q
Accession Number	`0001144204-17-058994`
Period End Date	20170930
Filing Date	20171114
Fiscal Year	2017
Fiscal Period	Q2
XBRL Instance	ameh-20170930.xml

Filing Contents

This filing contains the following financial statements:

Balance Sheet 72 Income Statement 68 Cash Flow Statement 70

Balance Sheet 72 line items

Line Item	Tag	Value	Unit	Period
Accounts receivable, net of allowance for doubtful accounts	`AllowanceForDoubtfulAccountsReceivableCurrent`	$381.02K	USD	Point-in-time
Accounts receivable, net of allowance for doubtful accounts	`AllowanceForDoubtfulAccountsReceivableCurrent`	$475.08K	USD	Point-in-time
Cash and cash equivalents	`CashAndCashEquivalentsAtCarryingValue`	$30.20M	USD	Point-in-time
Debt Issuance Costs, Current, Net	`DeferredFinanceCostsCurrentNet`	$161.00K	USD	Point-in-time
Cash and cash equivalents	`CashAndCashEquivalentsAtCarryingValue`	$8.66M	USD	Point-in-time
Cash and cash equivalents	`CashAndCashEquivalentsAtCarryingValue`	$9.27M	USD	Point-in-time
Debt Issuance Costs, Current, Net	`DeferredFinanceCostsCurrentNet`	$53.67K	USD	Point-in-time
Cash and cash equivalents	`CashAndCashEquivalentsAtCarryingValue`	$3.79M	USD	Point-in-time
Accounts receivable, net of allowance for doubtful accounts of $381,019 and $475,080, respectively	`AccountsReceivableNetCurrent`	$4.86M	USD	Point-in-time
Accounts receivable, net of allowance for doubtful accounts of $381,019 and $475,080, respectively	`AccountsReceivableNetCurrent`	$5.51M	USD	Point-in-time
Other receivables	`AccountsAndOtherReceivablesNetCurrent`	$372.33K	USD	Point-in-time
Other receivables	`AccountsAndOtherReceivablesNetCurrent`	$464.08K	USD	Point-in-time
Due from affiliates	`DueFromAffiliateCurrent`	$18.31K	USD	Point-in-time
Due from affiliates	`DueFromAffiliateCurrent`	-	USD	Point-in-time
Prepaid expenses and other current assets	`PrepaidExpenseAndOtherAssetsCurrent`	$298.48K	USD	Point-in-time
Prepaid expenses and other current assets	`PrepaidExpenseAndOtherAssetsCurrent`	$269.17K	USD	Point-in-time
Total current assets	`AssetsCurrent`	$35.73M	USD	Point-in-time
Total current assets	`AssetsCurrent`	$14.92M	USD	Point-in-time
Property and equipment, net	`PropertyPlantAndEquipmentNet`	$1.12M	USD	Point-in-time
Common Stock, par value (in dollars per share)	`CommonStockParOrStatedValuePerShare`	$0.00	USD	Point-in-time
Property and equipment, net	`PropertyPlantAndEquipmentNet`	$1.21M	USD	Point-in-time
Common Stock, par value (in dollars per share)	`CommonStockParOrStatedValuePerShare`	$0.00	USD	Point-in-time
Restricted cash	`RestrictedCashAndInvestmentsCurrent`	$765.06K	USD	Point-in-time
Common Stock, shares authorized	`CommonStockSharesAuthorized`	100.00M	shares	Point-in-time
Common Stock, shares authorized	`CommonStockSharesAuthorized`	100.00M	shares	Point-in-time
Restricted cash	`RestrictedCashAndInvestmentsCurrent`	$745.18K	USD	Point-in-time
Intangible assets, net	`IntangibleAssetsNetExcludingGoodwill`	$1.90M	USD	Point-in-time
Common Stock, shares issued	`CommonStockSharesIssued`	6.05M	shares	Point-in-time
Common Stock, shares issued	`CommonStockSharesIssued`	6.03M	shares	Point-in-time
Intangible assets, net	`IntangibleAssetsNetExcludingGoodwill`	$1.73M	USD	Point-in-time
Goodwill	`Goodwill`	$1.62M	USD	Point-in-time
Common Stock, shares outstanding	`CommonStockSharesOutstanding`	6.05M	shares	Point-in-time
Goodwill	`Goodwill`	$1.62M	USD	Point-in-time
Common Stock, shares outstanding	`CommonStockSharesOutstanding`	6.03M	shares	Point-in-time
Other assets	`OtherAssetsNoncurrent`	$225.36K	USD	Point-in-time
Other assets	`OtherAssetsNoncurrent`	$219.17K	USD	Point-in-time
TOTAL ASSETS	`Assets`	$41.17M	USD	Point-in-time
TOTAL ASSETS	`Assets`	$20.64M	USD	Point-in-time
Accounts payable and accrued liabilities	`AccountsPayableAndAccruedLiabilitiesCurrent`	$7.88M	USD	Point-in-time
Accounts payable and accrued liabilities	`AccountsPayableAndAccruedLiabilitiesCurrent`	$7.04M	USD	Point-in-time
Medical liabilities	`MedicalLiabilitiesCurrent`	$1.77M	USD	Point-in-time
Medical liabilities	`MedicalLiabilitiesCurrent`	$30.69M	USD	Point-in-time
Convertible note payable, net of debt issuance cost of $53,667 and $161,000, respectively	`ConvertibleNotesPayableCurrent`	$4.83M	USD	Point-in-time
Convertible note payable, net of debt issuance cost of $53,667 and $161,000, respectively	`ConvertibleNotesPayableCurrent`	$4.94M	USD	Point-in-time
Lines of credit	`LinesOfCreditCurrent`	$62.50K	USD	Point-in-time
Lines of credit	`LinesOfCreditCurrent`	$25.00K	USD	Point-in-time
Total current liabilities	`LiabilitiesCurrent`	$42.70M	USD	Point-in-time
Total current liabilities	`LiabilitiesCurrent`	$14.54M	USD	Point-in-time
Note payable - related party	`NotesPayableRelatedPartiesNoncurrent`	$5.00M	USD	Point-in-time
Note payable - related party	`NotesPayableRelatedPartiesNoncurrent`	$5.00M	USD	Point-in-time
Deferred rent liability	`DeferredRentCreditNoncurrent`	$683.50K	USD	Point-in-time
Deferred rent liability	`DeferredRentCreditNoncurrent`	$747.42K	USD	Point-in-time
Deferred tax liability	`DeferredTaxLiabilities`	$83.67K	USD	Point-in-time
Deferred tax liability	`DeferredTaxLiabilities`	$83.67K	USD	Point-in-time
TOTAL LIABILITIES	`Liabilities`	$48.46M	USD	Point-in-time
TOTAL LIABILITIES	`Liabilities`	$20.37M	USD	Point-in-time
COMMITMENTS AND CONTINGENCIES (see Note 8)	`CommitmentsAndContingencies`	-	USD	Point-in-time
COMMITMENTS AND CONTINGENCIES (see Note 8)	`CommitmentsAndContingencies`	-	USD	Point-in-time
Common stock, par value $0.001; 100,000,000 shares authorized; 6,052,518 and 6,033,518 shares issued and outstanding, respectively	`CommonStockValue`	$6.05K	USD	Point-in-time
Common stock, par value $0.001; 100,000,000 shares authorized; 6,052,518 and 6,033,518 shares issued and outstanding, respectively	`CommonStockValue`	$6.03K	USD	Point-in-time
Additional paid-in capital	`AdditionalPaidInCapital`	$26.33M	USD	Point-in-time
Additional paid-in capital	`AdditionalPaidInCapital`	$26.84M	USD	Point-in-time
Accumulated deficit	`RetainedEarningsAccumulatedDeficit`	$-37.65M	USD	Point-in-time
Accumulated deficit	`RetainedEarningsAccumulatedDeficit`	$-45.15M	USD	Point-in-time
Stockholders deficit attributable to Apollo Medical Holdings, Inc.	`StockholdersEquity`	$-353.88K	USD	Point-in-time
Stockholders deficit attributable to Apollo Medical Holdings, Inc.	`StockholdersEquity`	$-7.34M	USD	Point-in-time
Non-controlling interest	`MinorityInterest`	$624.25K	USD	Point-in-time
Non-controlling interest	`MinorityInterest`	$52.62K	USD	Point-in-time
Total stockholders (deficit) equity	`StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest`	$270.37K	USD	Point-in-time
Total stockholders (deficit) equity	`StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest`	$-7.29M	USD	Point-in-time
TOTAL LIABILITIES AND STOCKHOLDERS (DEFICIT) EQUITY	`LiabilitiesAndStockholdersEquity`	$20.64M	USD	Point-in-time
TOTAL LIABILITIES AND STOCKHOLDERS (DEFICIT) EQUITY	`LiabilitiesAndStockholdersEquity`	$41.17M	USD	Point-in-time

Income Statement 68 line items

Line Item	Tag	Value	Unit	Period
Net revenues	`Revenues`	$40.48M	USD	1 Quarter
Net revenues	`Revenues`	$82.06M	USD	2 Qtrs
Net revenues	`Revenues`	$26.99M	USD	2 Qtrs
Net revenues	`Revenues`	$14.62M	USD	1 Quarter
Cost of services	`CostOfServices`	$22.30M	USD	2 Qtrs
Cost of services	`CostOfServices`	$12.17M	USD	1 Quarter
Cost of services	`CostOfServices`	$39.10M	USD	1 Quarter
Cost of services	`CostOfServices`	$79.34M	USD	2 Qtrs
General and administrative	`GeneralAndAdministrativeExpense`	$8.29M	USD	2 Qtrs
General and administrative	`GeneralAndAdministrativeExpense`	$4.46M	USD	1 Quarter
General and administrative	`GeneralAndAdministrativeExpense`	$10.23M	USD	2 Qtrs
General and administrative	`GeneralAndAdministrativeExpense`	$5.35M	USD	1 Quarter
Depreciation and amortization	`DepreciationDepletionAndAmortization`	$311.20K	USD	2 Qtrs
Depreciation and amortization	`DepreciationDepletionAndAmortization`	$155.94K	USD	1 Quarter
Depreciation and amortization	`DepreciationDepletionAndAmortization`	$335.21K	USD	2 Qtrs
Depreciation and amortization	`DepreciationDepletionAndAmortization`	$170.56K	USD	1 Quarter
Total costs and expenses	`OperatingExpenses`	$89.88M	USD	2 Qtrs
Total costs and expenses	`OperatingExpenses`	$16.80M	USD	1 Quarter
Total costs and expenses	`OperatingExpenses`	$30.93M	USD	2 Qtrs
Total costs and expenses	`OperatingExpenses`	$44.60M	USD	1 Quarter
Loss from operations	`OperatingIncomeLoss`	$-4.11M	USD	1 Quarter
Loss from operations	`OperatingIncomeLoss`	$-7.82M	USD	2 Qtrs
Loss from operations	`OperatingIncomeLoss`	$-2.17M	USD	1 Quarter
Loss from operations	`OperatingIncomeLoss`	$-3.94M	USD	2 Qtrs
Interest expense	`InterestExpense`	$5.71K	USD	2 Qtrs
Interest expense	`InterestExpense`	$392.65K	USD	2 Qtrs
Interest expense	`InterestExpense`	$199.66K	USD	1 Quarter
Interest expense	`InterestExpense`	$3.05K	USD	1 Quarter
Gain (loss) on change in fair value of warrant liabilities	`GainLossOnDerivativeInstrumentsNetPretax`	$1.33M	USD	2 Qtrs
Gain (loss) on change in fair value of warrant liabilities	`GainLossOnDerivativeInstrumentsNetPretax`	-	USD	1 Quarter
Gain (loss) on change in fair value of warrant liabilities	`GainLossOnDerivativeInstrumentsNetPretax`	-	USD	2 Qtrs
Gain (loss) on change in fair value of warrant liabilities	`GainLossOnDerivativeInstrumentsNetPretax`	$511.11K	USD	1 Quarter
Other income (expense)	`OtherNonoperatingIncomeExpense`	$10.56K	USD	1 Quarter
Other income (expense)	`OtherNonoperatingIncomeExpense`	$12.53K	USD	2 Qtrs
Other income (expense)	`OtherNonoperatingIncomeExpense`	$54.63K	USD	1 Quarter
Other income (expense)	`OtherNonoperatingIncomeExpense`	$93.30K	USD	2 Qtrs
Total other income (expense), net	`NonoperatingIncomeExpense`	$518.62K	USD	1 Quarter
Total other income (expense), net	`NonoperatingIncomeExpense`	$1.34M	USD	2 Qtrs
Total other income (expense), net	`NonoperatingIncomeExpense`	$-145.03K	USD	1 Quarter
Total other income (expense), net	`NonoperatingIncomeExpense`	$-299.36K	USD	2 Qtrs
Loss before benefit from income taxes	`IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments`	$-2.60M	USD	2 Qtrs
Loss before benefit from income taxes	`IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments`	$-1.66M	USD	1 Quarter
Loss before benefit from income taxes	`IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments`	$-4.26M	USD	1 Quarter
Loss before benefit from income taxes	`IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments`	$-8.12M	USD	2 Qtrs
Benefit from income taxes	`IncomeTaxExpenseBenefit`	$-226.59K	USD	2 Qtrs
Benefit from income taxes	`IncomeTaxExpenseBenefit`	$-56.69K	USD	2 Qtrs
Benefit from income taxes	`IncomeTaxExpenseBenefit`	$-185.04K	USD	1 Quarter
Benefit from income taxes	`IncomeTaxExpenseBenefit`	$-26.86K	USD	1 Quarter
Net loss	`ProfitLoss`	$-4.23M	USD	1 Quarter
Net loss	`ProfitLoss`	$-2.37M	USD	2 Qtrs
Net loss	`ProfitLoss`	$-8.07M	USD	2 Qtrs
Net loss	`ProfitLoss`	$-1.47M	USD	1 Quarter
Net (income) loss attributable to non-controlling interest	`NetIncomeLossAttributableToNoncontrollingInterest`	$-112.34K	USD	1 Quarter
Net (income) loss attributable to non-controlling interest	`NetIncomeLossAttributableToNoncontrollingInterest`	$-571.62K	USD	2 Qtrs
Net (income) loss attributable to non-controlling interest	`NetIncomeLossAttributableToNoncontrollingInterest`	$303.53K	USD	2 Qtrs
Net (income) loss attributable to non-controlling interest	`NetIncomeLossAttributableToNoncontrollingInterest`	$-350.38K	USD	1 Quarter
Net loss attributable to Apollo Medical Holdings, Inc.	`NetIncomeLoss`	$-1.36M	USD	1 Quarter
Net loss attributable to Apollo Medical Holdings, Inc.	`NetIncomeLoss`	$-3.88M	USD	1 Quarter
Net loss attributable to Apollo Medical Holdings, Inc.	`NetIncomeLoss`	$-2.67M	USD	2 Qtrs
Net loss attributable to Apollo Medical Holdings, Inc.	`NetIncomeLoss`	$-7.49M	USD	2 Qtrs
Basic and diluted	`EarningsPerShareBasicAndDiluted`	$-1.24	USD	2 Qtrs
Basic and diluted	`EarningsPerShareBasicAndDiluted`	$-0.45	USD	2 Qtrs
Basic and diluted	`EarningsPerShareBasicAndDiluted`	$-0.23	USD	1 Quarter
Basic and diluted	`EarningsPerShareBasicAndDiluted`	$-0.64	USD	1 Quarter
Basic and diluted	`WeightedAverageNumberOfShareOutstandingBasicAndDiluted`	5.97M	shares	2 Qtrs
Basic and diluted	`WeightedAverageNumberOfShareOutstandingBasicAndDiluted`	6.03M	shares	2 Qtrs
Basic and diluted	`WeightedAverageNumberOfShareOutstandingBasicAndDiluted`	6.02M	shares	1 Quarter
Basic and diluted	`WeightedAverageNumberOfShareOutstandingBasicAndDiluted`	6.04M	shares	1 Quarter

Cash Flow Statement 70 line items

Line Item	Tag	Value	Unit	Period
Net loss	`ProfitLoss`	$-4.23M	USD	1 Quarter
Net loss	`ProfitLoss`	$-2.37M	USD	2 Qtrs
Net loss	`ProfitLoss`	$-8.07M	USD	2 Qtrs
Net loss	`ProfitLoss`	$-1.47M	USD	1 Quarter
Provision for doubtful accounts, net of recoveries	`ProvisionForDoubtfulAccounts`	$69.63K	USD	2 Qtrs
Provision for doubtful accounts, net of recoveries	`ProvisionForDoubtfulAccounts`	$90.04K	USD	2 Qtrs
Loss on disposal of property and equipment	`GainLossOnSaleOfPropertyPlantEquipment`	-	USD	2 Qtrs
Loss on disposal of property and equipment	`GainLossOnSaleOfPropertyPlantEquipment`	$-6.18K	USD	2 Qtrs
Depreciation and amortization expense	`DepreciationDepletionAndAmortization`	$311.20K	USD	2 Qtrs
Depreciation and amortization expense	`DepreciationDepletionAndAmortization`	$155.94K	USD	1 Quarter
Depreciation and amortization expense	`DepreciationDepletionAndAmortization`	$335.21K	USD	2 Qtrs
Depreciation and amortization expense	`DepreciationDepletionAndAmortization`	$170.56K	USD	1 Quarter
Stock-based compensation expense	`AllocatedShareBasedCompensationExpense`	$246.04K	USD	1 Quarter
Stock-based compensation expense	`AllocatedShareBasedCompensationExpense`	$195.24K	USD	1 Quarter
Stock-based compensation expense	`AllocatedShareBasedCompensationExpense`	$418.81K	USD	2 Qtrs
Stock-based compensation expense	`AllocatedShareBasedCompensationExpense`	$493.76K	USD	2 Qtrs
Amortization of deferred financing costs	`AdjustmentForAmortization`	$37.93K	USD	2 Qtrs
Amortization of deferred financing costs	`AdjustmentForAmortization`	$107.33K	USD	2 Qtrs
Gain on change in fair value of warrant liabilities	`GainLossOnDerivativeInstrumentsNetPretax`	$1.33M	USD	2 Qtrs
Gain on change in fair value of warrant liabilities	`GainLossOnDerivativeInstrumentsNetPretax`	-	USD	1 Quarter
Gain on change in fair value of warrant liabilities	`GainLossOnDerivativeInstrumentsNetPretax`	-	USD	2 Qtrs
Gain on change in fair value of warrant liabilities	`GainLossOnDerivativeInstrumentsNetPretax`	$511.11K	USD	1 Quarter
Restricted cash	`IncreaseDecreaseInRestrictedCashForOperatingActivities`	-	USD	2 Qtrs
Restricted cash	`IncreaseDecreaseInRestrictedCashForOperatingActivities`	$-19.88K	USD	2 Qtrs
Accounts receivable	`IncreaseDecreaseInAccountsReceivable`	$-559.30K	USD	2 Qtrs
Accounts receivable	`IncreaseDecreaseInAccountsReceivable`	$1.25M	USD	2 Qtrs
Other receivables	`IncreaseDecreaseInOtherReceivables`	$-91.75K	USD	2 Qtrs
Other receivables	`IncreaseDecreaseInOtherReceivables`	$-290.27K	USD	2 Qtrs
Due from affiliates	`IncreaseDecreaseDueFromAffiliates`	$-18.31K	USD	2 Qtrs
Due from affiliates	`IncreaseDecreaseDueFromAffiliates`	$-453.00	USD	2 Qtrs
Prepaid expenses and other current assets	`IncreaseDecreaseInPrepaidExpensesAndOtherCurrentAssets`	$136.45K	USD	2 Qtrs
Prepaid expenses and other current assets	`IncreaseDecreaseInPrepaidExpensesAndOtherCurrentAssets`	$29.31K	USD	2 Qtrs
Other assets	`IncreaseDecreaseInOtherOperatingAssets`	$-6.18K	USD	2 Qtrs
Other assets	`IncreaseDecreaseInOtherOperatingAssets`	$5.54K	USD	2 Qtrs
Accounts payable and accrued liabilities	`IncreaseDecreaseInAccountsPayableAndAccruedLiabilities`	$-27.60K	USD	2 Qtrs
Accounts payable and accrued liabilities	`IncreaseDecreaseInAccountsPayableAndAccruedLiabilities`	$-841.33K	USD	2 Qtrs
Deferred rent liability	`IncreaseDecreaseInOtherDeferredLiability`	$90.50K	USD	2 Qtrs
Deferred rent liability	`IncreaseDecreaseInOtherDeferredLiability`	$-63.91K	USD	2 Qtrs
Medical liabilities	`IncreaseDecreaseInMedicalLiabilities`	$-601.32K	USD	2 Qtrs
Medical liabilities	`IncreaseDecreaseInMedicalLiabilities`	$28.93M	USD	2 Qtrs
Net cash provided by (used in) operating activities	`NetCashProvidedByUsedInOperatingActivities`	$-4.41M	USD	2 Qtrs
Net cash provided by (used in) operating activities	`NetCashProvidedByUsedInOperatingActivities`	$21.55M	USD	2 Qtrs
Property and equipment acquired	`PaymentsToAcquirePropertyPlantAndEquipment`	$56.41K	USD	2 Qtrs
Property and equipment acquired	`PaymentsToAcquirePropertyPlantAndEquipment`	$205.78K	USD	2 Qtrs
Net cash used in investing activities	`NetCashProvidedByUsedInInvestingActivities`	$-56.41K	USD	2 Qtrs
Net cash used in investing activities	`NetCashProvidedByUsedInInvestingActivities`	$-205.78K	USD	2 Qtrs
Proceeds from lines of credit	`ProceedsFromLinesOfCredit`	$75.00K	USD	2 Qtrs
Proceeds from lines of credit	`ProceedsFromLinesOfCredit`	-	USD	2 Qtrs
Principal payments on lines of credit	`RepaymentsOfLinesOfCredit`	$62.50K	USD	2 Qtrs
Principal payments on lines of credit	`RepaymentsOfLinesOfCredit`	$37.50K	USD	2 Qtrs
Distributions to non-controlling interest shareholder	`PaymentsToMinorityShareholders`	-	USD	2 Qtrs
Distributions to non-controlling interest shareholder	`PaymentsToMinorityShareholders`	$1.05M	USD	2 Qtrs
Proceeds from the exercise of warrants/options	`ProceedsFromWarrantExercises`	$85.50K	USD	2 Qtrs
Proceeds from the exercise of warrants/options	`ProceedsFromWarrantExercises`	$172.00K	USD	2 Qtrs
Net cash provided by (used in) financing activities	`NetCashProvidedByUsedInFinancingActivities`	$-865.50K	USD	2 Qtrs
Net cash provided by (used in) financing activities	`NetCashProvidedByUsedInFinancingActivities`	$48.00K	USD	2 Qtrs
Net change in cash and cash equivalents	`CashAndCashEquivalentsPeriodIncreaseDecrease`	$-5.48M	USD	2 Qtrs
Net change in cash and cash equivalents	`CashAndCashEquivalentsPeriodIncreaseDecrease`	$21.54M	USD	2 Qtrs
Cash and cash equivalents, beginning of period	`CashAndCashEquivalentsAtCarryingValue`	$30.20M	USD	Point-in-time
Cash and cash equivalents, beginning of period	`CashAndCashEquivalentsAtCarryingValue`	$8.66M	USD	Point-in-time
Cash and cash equivalents, beginning of period	`CashAndCashEquivalentsAtCarryingValue`	$9.27M	USD	Point-in-time
Cash and cash equivalents, beginning of period	`CashAndCashEquivalentsAtCarryingValue`	$3.79M	USD	Point-in-time
Cash and cash equivalents, end of period	`CashAndCashEquivalentsAtCarryingValue`	$30.20M	USD	Point-in-time
Cash and cash equivalents, end of period	`CashAndCashEquivalentsAtCarryingValue`	$8.66M	USD	Point-in-time
Cash and cash equivalents, end of period	`CashAndCashEquivalentsAtCarryingValue`	$9.27M	USD	Point-in-time
Cash and cash equivalents, end of period	`CashAndCashEquivalentsAtCarryingValue`	$3.79M	USD	Point-in-time
Interest paid	`InterestPaidNet`	$872.00	USD	2 Qtrs
Interest paid	`InterestPaidNet`	$10.20K	USD	2 Qtrs
Income taxes paid	`IncomeTaxesPaid`	$16.40K	USD	2 Qtrs
Income taxes paid	`IncomeTaxesPaid`	$17.70K	USD	2 Qtrs

Data is extracted from SEC EDGAR XBRL filings. Values shown are as reported in the filing.